Announcements Trials
Browse Landscape

Phase

Phase 2 54Phase 3 11Phase NA 5Phase 1/2 5Phase 1 4Phase 4 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Unknown 5Not yet recruiting 5Recruiting 2

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other solid neoplasm 1Gynecologic 1

Conditions

Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

Standard of Care 25Exercise 24Interviews as Topic 19Blood Specimen Collection 18Educational Status 13Methods 12Surgical Procedures, Operative 11Drug Therapy 11Surveys and Questionnaires 10Radiosurgery 10Specimen Handling 9Saline Solution 9Acupuncture Therapy 9Paclitaxel 8Early Intervention, Educational 8Therapeutics 7Radiotherapy 7Magnetic Resonance Spectroscopy 7Electroacupuncture 7Cryotherapy 7Resistance Training 6Preoperative Exercise 6Practice Guidelines as Topic 6Palliative Care 6Dexmedetomidine 6Control Groups 6Colonoscopy 6Carboplatin 6tislelizumab 5Sentinel Lymph Node Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase NA × Not yet recruiting × tislelizumab × Clear all
NCT07535840 2026-04-17

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

Tongji Hospital

Phase NA Not yet recruiting
25 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07396090 2026-02-09

Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase NA Not yet recruiting
13 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT07067450 2025-07-16

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

Sichuan University

Phase NA Not yet recruiting
98 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06607926 2024-09-23

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Xuanwu Hospital, Beijing

Phase NA Not yet recruiting
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06363708 2024-04-12

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Zhongnan Hospital

Phase NA Not yet recruiting
20 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡